• Exploration of Targeted Anti-tumor Therapy

    eISSN: 2692-3114
    EiC: Nicola Normanno, MD, President of Italian Cancer Society (SIC)
    Frequency: Bimonthly
    APC: No Article Processing Charge before January 31, 2025
    Publishing Model: Open Access
    Peer Review Model: Single Blind
    Indexing & Archiving: PubMed/PMC, Scopus, Google Scholar
    Follow the journal:
    Follow the journal:
    Articles
    Open Access
    Original Article
    Hexachlorobenzene as a differential modulator of the conventional and metronomic chemotherapy response in triple negative breast cancer cells
    Aim: Triple negative breast cancer (TNBC) is usually treated with high doses of paclitaxel, whose effectiveness may be modulated by the action of environmental contaminants such as hexachlorobenz [...] Read more.
    Yamila Sanchez ... Alejandro Español
    Published: March 21, 2024 Explor Target Antitumor Ther. 2024;5:278–295
    DOI: https://doi.org/10.37349/etat.2024.00218
    This article belongs to the special issue Innovative Strategies to Target Triple-negative Breast Cancer
    View:139
    Download:7
    Times Cited: 0
    Open Access
    Review
    Improving the quality of patient care in lung cancer: key factors for successful multidisciplinary team working
    International Guidelines as well as Cancer Associations recommend a multidisciplinary approach to lung cancer care. A multidisciplinary team (MDT) can significantly improve treatment decision-making [...] Read more.
    Alessandro Morabito ... Giacomo Pascarella
    Published: March 21, 2024 Explor Target Antitumor Ther. 2024;5:260–277
    DOI: https://doi.org/10.37349/etat.2024.00217
    This article belongs to the special issue Integrated Approaches for Non-Small-Cell Lung Cancer
    View:124
    Download:11
    Times Cited: 0
    Open Access
    Mini Review
    Potential of targeting signal-transducing adaptor protein-2 in cancer therapeutic applications
    Adaptor proteins play essential roles in various intracellular signaling pathways. Signal-transducing adaptor protein-2 (STAP-2) is an adaptor protein that possesses pleckstrin homology (PH) and Src [...] Read more.
    Taiga Maemoto ... Tadashi Matsuda
    Published: March 07, 2024 Explor Target Antitumor Ther. 2024;5:251–259
    DOI: https://doi.org/10.37349/etat.2024.00216
    View:173
    Download:12
    Times Cited: 0
    Open Access
    Review
    Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response
    Triple negative breast cancer (TNBC) represents an aggressive disease associated with a high risk of recurrence after curative treatment and a poor prognosis in the metastatic setting. Chemotherapy  [...] Read more.
    Pierluigi De Santis ... Palma Fedele
    Published: February 28, 2024 Explor Target Antitumor Ther. 2024;5:232–250
    DOI: https://doi.org/10.37349/etat.2024.00215
    This article belongs to the special issue Innovative Strategies to Target Triple-negative Breast Cancer
    View:451
    Download:21
    Times Cited: 0
    Open Access
    Case Report
    A case of immunotherapy-induced thyroiditis
    Immunotherapy treatments for cancer are known to cause adverse thyroid events which present a diagnostic challenge to clinicians and radiologists. This case report highlights the importance of a hig [...] Read more.
    George Pears ... Joseph Sacco
    Published: February 28, 2024 Explor Target Antitumor Ther. 2024;5:225–231
    DOI: https://doi.org/10.37349/etat.2024.00214
    This article belongs to the special issue Novel Strategies and Targets for Immunotherapy of Cancer
    View:340
    Download:19
    Times Cited: 0
    Open Access
    Review
    Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin’s lymphoma
    Radioimmunotherapy (RIT) is a therapy that combines a radioactive nucleotide with a monoclonal antibody (mAb). RIT enhances the therapeutic effect of mAb and reduces toxicity compared with conventio [...] Read more.
    Hiroki Goto ... Seiji Okada
    Published: February 28, 2024 Explor Target Antitumor Ther. 2024;5:208–224
    DOI: https://doi.org/10.37349/etat.2024.00213
    This article belongs to the special issue Novel Strategies and Targets for Immunotherapy of Cancer
    View:357
    Download:20
    Times Cited: 0
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead”  [...] Read more.
    Robert I. Troup ... Matthias G. J. Baud
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273–312
    DOI: https://doi.org/10.37349/etat.2020.00018
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:22534
    Download:2877
    Open Access
    Review
    The impact of tumour pH on cancer progression: strategies for clinical intervention
    Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi [...] Read more.
    Carol Ward ... Simon P Langdon
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71–100
    DOI: https://doi.org/10.37349/etat.2020.00005
    View:13927
    Download:662
    Open Access
    Review
    Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
    Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell  [...] Read more.
    Rachael Arthur ... Graham Packham
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:131–152
    DOI: https://doi.org/10.37349/etat.2020.00009
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:6837
    Download:276
    Open Access
    Review
    Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer
    The Fanconi anaemia (FA) pathway is an important mechanism for cellular DNA damage repair, which functions to remove toxic DNA interstrand crosslinks. This is particularly relevant in the context of [...] Read more.
    Sarah J Taylor ... Simon P Langdon
    Published: February 29, 2020 Explor Target Antitumor Ther. 2020;1:26–52
    DOI: https://doi.org/10.37349/etat.2020.00003
    View:6169
    Download:179
    Times Cited: 0
    Open Access
    Review
    PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors
    BCL-XL is an anti-apoptotic protein that plays an important role in tumorigenesis, metastasis, and intrinsic or therapy-induced cancer drug resistance. More recently, BCL-XL has also been identified [...] Read more.
    Peiyi Zhang ... Guangrong Zheng
    Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:259–272
    DOI: https://doi.org/10.37349/etat.2020.00017
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:5283
    Download:277
    Open Access
    Review
    Novel approaches for the rational design of PROTAC linkers
    Proteolysis targeting chimeras (PROTACs) represent a promising class of hetero-bivalent molecules that facilitate ubiquitination of a target protein by simultaneously binding and bringing together b [...] Read more.
    Almaz Zagidullin ... Emil Bulatov
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:381–390
    DOI: https://doi.org/10.37349/etat.2020.00023
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:5132
    Download:366
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead”  [...] Read more.
    Robert I. Troup ... Matthias G. J. Baud
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273–312
    DOI: https://doi.org/10.37349/etat.2020.00018
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:22534
    Download:2877
    Open Access
    Perspective
    Encouraging probiotics for the prevention and treatment of immune-related adverse events in novel immunotherapies against malignant glioma
    Among the malignant tumors in the central nervous system (CNS), glioma is the most challenging tumor to the public society, which accounts for the majority of intracranial malignant tumors with impa [...] Read more.
    Sayuri Yoshikawa ... Satoru Matsuda
    Published: December 27, 2022 Explor Target Antitumor Ther. 2022;3:817–827
    DOI: https://doi.org/10.37349/etat.2022.00114
    This article belongs to the special issue Theranostic Frontiers in Neuro-Oncology
    View:2758
    Download:1254
    Open Access
    Perspective
    Potential tactics with vitamin D and certain phytochemicals for enhancing the effectiveness of immune-checkpoint blockade therapies
    Immunotherapy strategies targeting immune checkpoint molecules such as programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) are revolutionizing oncology. However,  [...] Read more.
    Ai Tsuji ... Satoru Matsuda
    Published: June 30, 2023 Explor Target Antitumor Ther. 2023;4:460–473
    DOI: https://doi.org/10.37349/etat.2023.00145
    This article belongs to the special issue Cancer Immunotherapy and Tumor Microenvironment
    View:1612
    Download:741
    Open Access
    Review
    The impact of tumour pH on cancer progression: strategies for clinical intervention
    Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi [...] Read more.
    Carol Ward ... Simon P Langdon
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71–100
    DOI: https://doi.org/10.37349/etat.2020.00005
    View:13927
    Download:662
    Open Access
    Perspective
    Potential tactics with certain gut microbiota for the treatment of unresectable hepatocellular carcinoma
    Hepatocellular carcinoma (HCC) constitutes an extremely malignant form of primary liver cancer. Intricate connections linking to the immune system might be associated with the pathogenesis of HCC. M [...] Read more.
    Sayuri Yoshikawa ... Satoru Matsuda
    Published: August 24, 2023 Explor Target Antitumor Ther. 2023;4:556–568
    DOI: https://doi.org/10.37349/etat.2023.00152
    This article belongs to the special issue Cancer Immunotherapy and Tumor Microenvironment
    View:1459
    Download:613
    Open Access
    Review
    Novel approaches for the rational design of PROTAC linkers
    Proteolysis targeting chimeras (PROTACs) represent a promising class of hetero-bivalent molecules that facilitate ubiquitination of a target protein by simultaneously binding and bringing together b [...] Read more.
    Almaz Zagidullin ... Emil Bulatov
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:381–390
    DOI: https://doi.org/10.37349/etat.2020.00023
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:5132
    Download:366
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead”  [...] Read more.
    Robert I. Troup ... Matthias G. J. Baud
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273–312
    DOI: https://doi.org/10.37349/etat.2020.00018
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:22534
    Download:2877
    Open Access
    Review
    The impact of tumour pH on cancer progression: strategies for clinical intervention
    Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi [...] Read more.
    Carol Ward ... Simon P Langdon
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71–100
    DOI: https://doi.org/10.37349/etat.2020.00005
    View:13927
    Download:662
    Open Access
    Review
    Novel approaches for the rational design of PROTAC linkers
    Proteolysis targeting chimeras (PROTACs) represent a promising class of hetero-bivalent molecules that facilitate ubiquitination of a target protein by simultaneously binding and bringing together b [...] Read more.
    Almaz Zagidullin ... Emil Bulatov
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:381–390
    DOI: https://doi.org/10.37349/etat.2020.00023
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:5132
    Download:366
    Open Access
    Review
    The clinical advances of proteolysis targeting chimeras in oncology
    Proteolysis targeting chimeras (PROTACs) are a class of small molecules designed to target proteins for degradation. Their novel and unique modes of action provide PROTACs with the potential for the [...] Read more.
    Hao Xie ... Jason B. Fleming
    Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:511–521
    DOI: https://doi.org/10.37349/etat.2021.00061
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:3933
    Download:212
    Open Access
    Review
    New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
    Antibody-drug conjugates (ADCs) have changed the treatment of breast cancer (BC) in more recent years. BC is a heterogenous group of malignancies with a broad range of histopathological characterist [...] Read more.
    Kira-Lee Koster ... Markus Joerger
    Published: February 24, 2022 Explor Target Antitumor Ther. 2022;3:27–36
    DOI: https://doi.org/10.37349/etat.2022.00069
    This article belongs to the special issue Antibody-Drug Conjugates
    Open Access
    Review
    PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors
    BCL-XL is an anti-apoptotic protein that plays an important role in tumorigenesis, metastasis, and intrinsic or therapy-induced cancer drug resistance. More recently, BCL-XL has also been identified [...] Read more.
    Peiyi Zhang ... Guangrong Zheng
    Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:259–272
    DOI: https://doi.org/10.37349/etat.2020.00017
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:5283
    Download:277
    Special Issues